Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.
Christopher J. Calhoun
Advertisement
Christopher J. Calhoun is Chairman & CEO of PARACRINE, a biotechnology company developing the world’s first autologous, device-based disease modifying cell therapy for chronic conditions into late (approval) stage clinical trials based on robust prior clinical data.
Articles by Christopher J. Calhoun
Advertisement
Latest Updated Articles
Escaping the “Valley of Death:” The Funding Process for Biotechnology CompaniesPublished: January 4th 2022 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
4
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
5
